Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$163M+7.2%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$22.37M-5.7%
Schering-Plough logo
Schering-PloughSGP
$1.57M
TTR
Turn Therapeutics Inc.TTRX
$80.38K
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$266.8M+13.8%
Warby Parker logo
Warby ParkerWRBY
$250.98M+9.9%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.97B+40.7%
Enterprise value$2.86B+36.8%
P/S4.9×-2.2×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemAmountsAmounts
Thereafter15,396
Total future lease payments, undiscounted27,654
(Less): Imputed interest(11,014)
(Less): Tenant improvement allowance(591)
Present value of operating lease payments$$16,049
Operating lease liability, current154
Operating lease liability, non-current15,895
Total operating lease liability$$16,049

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total)?
Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liabilities (total) of $16.05M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total) changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total) increased by 4962.8% year-over-year, from $317K to $16.05M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total)?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total) has grown at a 66.4% compound annual growth rate (CAGR), from $831K to $10.6M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude